Association Between BMP-2 and Carcinogenicity

被引:68
作者
Skovrlj, Branko [1 ]
Koehler, Steven M. [2 ]
Anderson, Paul A. [3 ]
Qureshi, Sheeraz A. [2 ]
Hecht, Andrew C. [2 ]
Iatridis, James C. [2 ]
Cho, Samuel K. [2 ]
机构
[1] Icahn Sch Med Mt Sinai, Dept Neurosurg, New York, NY 10029 USA
[2] Icahn Sch Med Mt Sinai, Dept Orthopaed Surg, New York, NY 10029 USA
[3] Univ Wisconsin, Dept Orthopaed & Rehabil, Madison, WI USA
关键词
bone morphogenetic protein; carcinogenicity; fusion; InFuse (R); malignancy; rhBMP-2; Spine surgery; BONE-MORPHOGENETIC PROTEIN-2; HUMAN BREAST-CANCER; NECROSIS-FACTOR-ALPHA; BETA FAMILY-MEMBERS; NF-KAPPA-B; PROSTATE-CANCER; GENE-EXPRESSION; TGF-BETA; IN-VITRO; METASTATIC PROSTATE;
D O I
10.1097/BRS.0000000000001126
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Study Design.Literature review.Objective.To evaluate the association between recombinant human bone morphogenetic protein-2 (rhBMP-2) and malignancy.Summary of Background Data.The use of rhBMP-2 in spine surgery has been the topic of much debate as studies assessing the association between rhBMP-2 and malignancy have come to conflicting conclusions.Methods.A systematic review of the literature was performed using the PubMed-National Library of Medicine/National Institute of Health databases. Only non-clinical studies directly addressing BMP-2 and cancer were included. Articles were categorized by study type (animal, in vitro cell line/human/animal), primary malignancy, cancer attributes, and whether BMP-2 was pro-malignancy or not.Results.A total of 4,131 articles were reviewed. Of those, 515 articles made reference to both BMP-2 and cancer, 99 of which were found to directly examine the role of BMP-2 in cancer. Seventy-five studies were in vitro and 24 were animal studies. Forty-three studies concluded that BMP-2 enhanced cancer function, whereas 18 studies found that BMP-2 suppressed malignancy. Thirty-six studies did not examine whether BMP-2 enhanced or suppressed cancer function. Fifteen studies demonstrated BMP-2 dose dependence (9 enhancement, 6 suppression) and one study demonstrated no dose dependence. Nine studies demonstrated BMP-2 time dependence (6 enhancement, 3 suppression). However, no study demonstrated that BMP-2 caused cancer de novo.Conclusion.Currently, conflicting data exist with regard to the effect of exogenous BMP-2 on cancer. The majority of studies addressed the role of BMP-2 in prostate (17%), breast (17%), and lung (15%) cancers. Most were in vitro studies (75%) and examined cancer invasiveness and metastatic potential (37%). Of 99 studies, there was no demonstration of BMP-2 causing cancer de novo. However, 43% of studies suggested that BMP-2 enhances tumor function, motivating more definitive research on the topic that also includes clinically meaningful dose- and time-dependence.Level of Evidence: 2
引用
收藏
页码:1862 / 1871
页数:10
相关论文
共 131 条
  • [1] [Anonymous], CARCINOGENESIS
  • [2] [Anonymous], STEM CELLS
  • [3] [Anonymous], KNOWN PROB HUM CARC
  • [4] [Anonymous], SUMM SAF EFF DAT PRE
  • [5] [Anonymous], INFUSE BON GRAFT LT
  • [6] [Anonymous], 2014, CANC FACTS FIG 2014
  • [7] Identification of bone morphogenetic proteins and their receptors in human breast cancer cell lines: Importance of BMP2
    Arnold, SF
    Tims, E
    McGrath, BE
    [J]. CYTOKINE, 1999, 11 (12) : 1031 - 1037
  • [8] BMP-induced growth suppression in colon cancer cells is mediated by p21WAF1 stabilization and modulated by RAS/ERK
    Beck, Stayce E.
    Jung, Barbara H.
    Del Rosario, Eunice
    Gomez, Jessica
    Carethers, John M.
    [J]. CELLULAR SIGNALLING, 2007, 19 (07) : 1465 - 1472
  • [9] EXPRESSION OF BONE MORPHOGENETIC PROTEINS IN HUMAN PROSTATIC ADENOCARCINOMA AND BENIGN PROSTATIC HYPERPLASIA
    BENTLEY, H
    HAMDY, FC
    HART, KA
    SEID, JM
    WILLIAMS, JL
    JOHNSTONE, D
    RUSSELL, RGG
    [J]. BRITISH JOURNAL OF CANCER, 1992, 66 (06) : 1159 - 1163
  • [10] The positive correlation between gene expression of the two angiogenic factors: VEGF and BMP-2 in lung cancer patients
    Bieniasz, Magdalena
    Oszajca, Katarzyna
    Eusebio, Mak
    Kordiak, Jacek
    Bartkowiak, Jacek
    Szemraj, Janusz
    [J]. LUNG CANCER, 2009, 66 (03) : 319 - 326